Characteristics of changes in blood biochemical parameters during dynamic observation in patients with COVID-19 and in the post-COVID period

Kostina O.V.; Galova E.A.; Lyubavina N.A.; Presnyakova M.V.; Vedunova M.V.

doi:https://doi.org/10.17116/profmed20222505186

Kostina O.V.

Federal State Budgetary Educational Institution of Higher Education «Privolzhsky Research Medical University» of the Ministry of Health of Russia

Galova E.A.

Federal State Budgetary Educational Institution of Higher Education «Privolzhsky Research Medical University» of the Ministry of Health of Russia

Lyubavina N.A.

Federal State Budgetary Educational Institution of Higher Education «Privolzhsky Research Medical University» of the Ministry of Health of Russia

Presnyakova M.V.

Federal State Budgetary Educational Institution of Higher Education «Privolzhsky Research Medical University» of the Ministry of Health of Russia

Vedunova M.V.

National Research Lobachevsky State University of Nizhny Novgorod

Characteristics of changes in blood biochemical parameters during dynamic observation in patients with COVID-19 and in the post-COVID period

Authors:

Kostina O.V., Galova E.A., Lyubavina N.A., Presnyakova M.V., Vedunova M.V.

More about the authors

Journal: Russian Journal of Preventive Medicine. 2022;25(5): 86‑92

DOI: 10.17116/profmed20222505186

Read: 7038 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kostina OV, Galova EA, Lyubavina NA, Presnyakova MV, Vedunova MV. Characteristics of changes in blood biochemical parameters during dynamic observation in patients with COVID-19 and in the post-COVID period. Russian Journal of Preventive Medicine. 2022;25(5):86‑92. (In Russ.)
https://doi.org/10.17116/profmed20222505186

Подписка 2026 Профилактическая медицина (Russian Journal of Preventive Medicine)

Использование инфографики авторами научных работ

Close metadata

PURPOSE OF THE STUDY

To analyze changes in blood biochemical parameters in the acute period of COVID-19, in the period of early and late convalescence during dynamic observation of patients.

MATERIAL AND METHODS

In 50 patients in the acute period of COVID-19 and in the post-COVID period, the content of glucose, creatinine, urea, total protein, albumin, total bilirubin, transaminases, C-reactive protein in the blood serum was studied.

RESULTS

In the acute period of COVID-19 and in the post-COVID period, cases of hyperglycemia were recorded (n=7 and n=6, respectively), not associated with a history of diabetes mellitus. During COVID-19, creatinine levels increased in almost every fourth patient and returned to normal in most patients during the convalescence period. Increased activity of transaminases during the illness was recorded in 64% of patients, in most patients in the post-COVID period, the indicators returned to normal. During hospitalization, an increased content of total bilirubin was determined in 1 patient, after 10—14 days — in 14% of patients, during the period of convalescence — in 6%. The course of the disease was characterized by hypoalbuminemia and a decrease in the concentration of total protein by 19%. In the period of convalescence, an increase in the concentration of total protein by 10% was recorded; a year after the infection, normalization of the albumin level was noted. The course of COVID-19 was accompanied by a significant increase in the level of C-reactive protein, which decreased in the dynamics of observations; after 2—3 months, the increase in the level remained in 12%, after a year — in 16% of patients.

CONCLUSION

The acute period of COVID-19 was characterized by pronounced changes in the biochemical parameters of the blood. In the post-COVID period, deviations from the norm of certain indicators were noted in more than 30% of patients. This indicates the need for dynamic monitoring of laboratory parameters, which can help prevent the development of comorbidities after suffering COVID-19.

Keywords:

COVID-19

acute period

convalescence

biochemical parameters of blood serum

Authors:

Kostina O.V.

Federal State Budgetary Educational Institution of Higher Education «Privolzhsky Research Medical University» of the Ministry of Health of Russia

Galova E.A.

Federal State Budgetary Educational Institution of Higher Education «Privolzhsky Research Medical University» of the Ministry of Health of Russia

Lyubavina N.A.

Federal State Budgetary Educational Institution of Higher Education «Privolzhsky Research Medical University» of the Ministry of Health of Russia

Presnyakova M.V.

Federal State Budgetary Educational Institution of Higher Education «Privolzhsky Research Medical University» of the Ministry of Health of Russia

Vedunova M.V.

National Research Lobachevsky State University of Nizhny Novgorod

Received:

27.01.2022

Accepted:

23.03.2022

Close metadata

References:

Iwasaki M, Saito J, Zhao H, Sakamoto A, Hirota K, Ma D. Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications. Inflammation. 2021;44(1):13-34. https://doi.org/10.1007/s10753-020-01337-3
Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infectious Diseases. 2021;53(10):737-754. https://doi.org/10.1080/23744235.2021.1924397
Callard F, Perego E. How and why patients made Long Covid. Social Science and Medicine (1982). 2021;268:113426. https://doi.org/10.1016/j.socscimed.2020.113426
Bansal R, Gubbi S, Koch CA. COVID-19 and Chronic Fatigue Syndrome: An Endocrine Perspective [published online ahead of print, 2021 Dec 3]. Journal of Clinical and Translational Endocrinology. 2021;100284. https://doi.org/10.1016/j.jcte.2021.100284
Fernández-Lázaro D, Sánchez-Serrano N, Mielgo-Ayuso J, García-Hernández JL, González-Bernal JJ, Seco-Calvo J. Long COVID a New Derivative in the Chaos of SARS-CoV-2 Infection: The Emergent Pandemic? Journal of Clinical Medicine. 2021;10(24):5799. https://doi.org/10.3390/jcm10245799
Guerrero Caballero S, Bilbao Fernández S. [Persistence of SARS-CoV-2 virus as an etiologic cause of long-lasting symptomatology in patients with persistent COVID-19]. Medicina General y de Familia. 2021;10:85-90. https://doi.org/10.24038/mgyf.2021.027
Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, Cho A, Jankovic M, Schaefer-Babajew D, Oliveira TY, Cipolla M, Viant C, Barnes CO, Bram Y, Breton G, Hägglöf T, Mendoza P, Hurley A, Turroja M, Gordon K, Millard KG, Ramos V, Schmidt F, Weisblum Y, Jha D, Tankelevich M, Martinez-Delgado G, Yee J, Patel R, Dizon J, Unson-O’Brien C, Shimeliovich I, Robbiani DF, Zhao Z, Gazumyan A, Schwartz RE, Hatziioannou T, Bjorkman PJ, Mehandru S, Bieniasz PD, Caskey M, Nussenzweig MC. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639-644. https://doi.org/10.1038/s41586-021-03207-w
Crook H, Raza S, Nowell J, Young M, Edison P. Long covid — mechanisms, risk factors, and management. British Medical Journal. 2021;374:n1648. https://doi.org/10.1136/bmj.n1648
Lima-Martínez MM, Carrera Boada C, Madera-Silva MD, Marín W, Contreras M. COVID-19 and diabetes: A bidirectional relationship. COVID-19 y diabetes mellitus: una relación bidireccional. Clinica e Investigacion en Arteriosclerosis. 2021;33(3):151-157. https://doi.org/10.1016/j.arteri.2020.10.001
Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. International Journal of Infectious Diseases. 2020;94:91-95. https://doi.org/10.1016/j.ijid.2020.03.017
Hayden MR. An Immediate and Long-Term Complication of COVID-19 May Be Type 2 Diabetes Mellitus: The Central Role of β-Cell Dysfunction, Apoptosis and Exploration of Possible Mechanisms. Cells. 2020;9(11):2475. https://doi.org/10.3390/cells9112475
Accili D. Can COVID-19 cause diabetes? Nature Metabolism. 2021;3(2): 123-125. https://doi.org/10.1038/s42255-020-00339-7
Sardu C, D’Onofrio N, Balestrieri ML, Barbieri M, Rizzo MR, Messina V, Maggi P, Coppola N, Paolisso G, Marfella R. Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control? Diabetes Care. 2020;43(7):1408-1415. https://doi.org/10.2337/dc20-0723
Rubino F, Amiel SA, Zimmet P, Alberti G, Bornstein S, Eckel RH, Mingrone G, Boehm B, Cooper ME, Chai Z, Del Prato S, Ji L, Hopkins D, Herman WH, Khunti K, Mbanya JC, Renard E. New-Onset Diabetes in Covid-19. The New England Journal of Medicine. 2020;383(8):789-790. https://doi.org/10.1056/NEJMc2018688
Mohamadi Yarijani Z, Najafi H. Kidney injury in COVID-19 patients, drug development and their renal complications: Review study. Biomedicine and Pharmacotherapy. 2021;142:111966. https://doi.org/10.1016/j.biopha.2021.111966
Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, Paranjpe I, Somani S, Richter F, Miotto R, Lala A, Kia A, Timsina P, Li L, Freeman R, Chen R, Narula J, Just AC, Horowitz C, Fayad Z, Cordon-Cardo C, Schadt E, Levin MA, Reich DL, Fuster V, Murphy B, He JC, Charney AW, Böttinger EP, Glicksberg BS, Coca SG, Nadkarni GN; Mount Sinai COVID Informatics Center (MSCIC). AKI in Hospitalized Patients with COVID-19. Journal of the American Society of Nephrology: JASN. 2021;32(1):151-160. https://doi.org/10.1681/ASN.2020050615
Zhou M, Tan X, Luo P, Xu J, Yin Z, Liao T, Wang S, Wang Z, Jin Y. Changes in glomerular filtration rate and metabolomic differences in severely ill coronavirus disease survivors 3 months after discharge. Biochimica et Biophysica Acta. Molecular Basis of Disease. 2021;1868(1):166289. https://doi.org/10.1016/j.bbadis.2021.166289
Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Li Y, Xie W, Cui D, Shang L, Fan G, Xu J, Wang G, Wang Y, Zhong J, Wang C, Wang J, Zhang D, Cao B. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270): 220-232. https://doi.org/10.1016/S0140-6736(20)32656-8
Schytz PA, Nissen AB, Torp-Pedersen C, Gislason GH, Nelveg-Kristensen KE, Hommel K, Gerds TA, Carlson N. Creatinine increase following initiation of antihypertensives is associated with cardiovascular risk: a nationwide cohort study. Journal of Hypertension. 2020;38(12):2519-2526. https://doi.org/10.1097/HJH.0000000000002573
Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver International. 2020;40(5):998-1004. https://doi.org/10.1111/liv.14435
Wang X, Lei J, Li Z, Yan L. Potential Effects of Coronaviruses on the Liver: An Update. Frontiers in Medicine. 2021;8:651658. https://doi.org/10.3389/fmed.2021.651658
Nardo AD, Schneeweiss-Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological mechanisms of liver injury in COVID-19. Liver International. 2021;41(1):20-32. https://doi.org/10.1111/liv.14730
Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, Pratt DS, Russo MW, Schilsky ML, Verna EC, Loomba R, Cohen DE, Bezerra JA, Reddy KR, Chung RT. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology. 2020;72(1):287-304. https://doi.org/10.1002/hep.31281
McConnell MJ, Kawaguchi N, Kondo R, Sonzogni A, Licini L, Valle C, Bonaffini PA, Sironi S, Alessio MG, Previtali G, Seghezzi M, Zhang X, Lee AI, Pine AB, Chun HJ, Zhang X, Fernandez-Hernando C, Qing H, Wang A, Price C, Sun Z, Utsumi T, Hwa J, Strazzabosco M, Iwakiri Y. Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. Journal of Hepatology. 2021;75(3):647-658. https://doi.org/10.1016/j.jhep.2021.04.050
Zarifian A, Zamiri Bidary M, Arekhi S, Rafiee M, Gholamalizadeh H, Amiriani A, Ghaderi MS, Khadem-Rezaiyan M, Amini M, Ganji A.Gastrointestinal and hepatic abnormalities in patients with confirmed COVID-19: A systematic review and meta-analysis. Journal of Medical Virology. 2021;93(1):336-350. https://doi.org/10.1002/jmv.26314
Hu J, Wang Y. The Clinical Characteristics and Risk Factors of Severe COVID-19. Gerontology. 2021;67(3):255-266. https://doi.org/10.1159/000513400
Boraschi P, Giugliano L, Mercogliano G, Donati F, Romano S, Neri E. Abdominal and gastrointestinal manifestations in COVID-19 patients: Is imaging useful? World Journal of Gastroenterology. 2021;27(26):4143-4159. https://doi.org/10.3748/wjg.v27.i26.4143
Pinchuk TV, Orlova NV, Suranova TG, Bonkalo TI. Mechanisms of liver damage in COVID 19. Medicinskij alfavit. 2020;1(19):39-46. (In Russ.). https://doi.org/10.33667/2078-5631-2020-19-39-46
Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, Berger JS. C-reactive protein and clinical outcomes in patients with COVID-19. European Heart Journal. 2021;42(23):2270-2279. https://doi.org/10.1093/eurheartj/ehaa1103